Search the Newsreel

AstraZeneca Secures EU Nod For Etcamah In Advanced Breast Cancer

(RTTNews) - AstraZeneca (AZN) on Thursday announced that the company's Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been approved in the European Union or EU for the treatment of adult patients for an advanced breast …

REG - AstraZeneca PLC - Etcamah approved in the EU for ER+ breast cancer

AstraZeneca's Etcamah (camizestrant), in combination with a CDK4/6 inhibitor, has received approval in the EU for treating adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation. This approval, based on the SERENA-6 Phase III trial, demonstrated a 56% …

Jefferies says September lung data can offset AstraZeneca trial failure

Jefferies believes that forthcoming detailed data on AstraZeneca's experimental lung drug, tozorakimab, could mitigate the impact of a recent heart trial failure. The bank reiterated its "buy" rating and a 17,500p price target, citing the drug's potential to treat chronic obstructive pulmonary disease regardless …

Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics

Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.50 per share in its upcoming report, which indicates a year-over-year increase of 14.7%. Revenues are expected to be $15.31 billion, up 5.9% from the year-ago quarter. The current level reflects a downward …

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma plc NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront. Cliramitug is a Phase …

Earnings Preview: AstraZeneca to Report Financial Results on July 27

This article provides an earnings preview for AstraZeneca (AZN), stating that the pharmaceutical giant is scheduled to report its financial results on July 27. Investors will be closely watching for details on the company's performance, including revenue growth from new drug launches and overall …

ASTRAZENECA : JP Morgan gives a Buy rating

JP Morgan analyst Richard Vosser has reaffirmed a "Buy" rating for AstraZeneca PLC, keeping the target price unchanged at GBX 12380. The pharmaceutical company's stock shows a 0.90% increase, with recent news including Novartis's strong profit and various updates in the biotech sector. AstraZeneca's …

AstraZeneca slips Monday, underperforms market

AstraZeneca PLC (AZN) shares fell 1.70% on Monday, closing at £123.80, underperforming the broader market as the FTSE 100 Index declined 0.71%. The company's stock is now 21.31% below its 52-week high of £157.32, which was reached on February 18th.

Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know

Astrazeneca (AZN) experienced a more significant drop than the broader market, closing down 2.59% while the S&P 500 had a smaller loss. Over the past month, AZN's stock fell 3.45%, underperforming both the Medical sector and the S&P 500. Investors are anticipating its upcoming …

Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form …

AstraZeneca needs a shot in the arm to hit $80bn revenue target

AstraZeneca Pharma India files BRSR for FY26

Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC CDx, an FDA approved companion …

AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against AstraZeneca PLC (AZN) after its late-stage Phase-3 CARDIO-TTransform trial for the amyloid cardiomyopathy treatment Wainua failed to meet its primary endpoint, causing a significant drop in the company's American Depositary Share (ADS) price. The …

AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume

This article provides details on AstraZeneca Tokenized Stock (AZNX), a digital asset tracking AstraZeneca PLC's share price. It covers current price, market cap, trading volume, and market performance statistics. The article also explains AZNX's function as a tracker certificate within the xStocks ecosystem, offering …

AstraZeneca Pharma Appoints FICCI Veteran Praveen K Mittal with 30 Years Experience

AstraZeneca Pharma India closes trading window until Q1FY27 results

AstraZeneca Pharma India Loses 2 Key Executives Amid Operational Shifts; Focus on Q1 FY27

AstraZeneca India Wins Approval To Sell Enhertu Targeting India's 1.4 Million Annual Cancer Cases

We Think That There Are Issues Underlying AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings

Here's Why AstraZeneca Pharma India (NSE:ASTRAZEN) Has Caught The Eye Of Investors

AstraZeneca Falls 7% on Q4 Profit Drop, Margin Hit

AstraZeneca FY26 revenue rises 33%, recommends ₹36 dividend

AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock

AstraZeneca Pharma India Q4 profit drops 23% despite strong revenue growth

AstraZeneca Pharma Q4 Results: Profit Down 23%, Revenue Rises

AstraZeneca India Secures CDSCO Approval for 100 mg Calquence in Mantle Cell Lymphoma Expansion

AstraZeneca Pharma Partners With Roche To Target 2 Cancer Types Via Advanced Pathology

Leerink raises AstraZeneca stock price target to $220 on COPD drug data

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) market cap surged ₹8.0b last week, public companies who have a lot riding on the company were rewarded

AstraZeneca Pharma India Receives Final Income Tax Assessment Order for AY 2022-23

AstraZeneca Pharma India Ltd. Share Price Today - AstraZeneca Pharma India Ltd. Stock Price Live NSE/BSE

AstraZeneca Pharma India shares surge over 3% on new Hyperkalaemia drug deal with Sun Pharma

AstraZeneca Pharma India Exits Manufacturing Operations, Surrenders License

We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Can Stay On Top Of Its Debt